Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
In High-Risk Patients, Most DOACs Reduce Stroke Risk Without Increasing Bleeding Risk vs Warfarin
August 16th 2021Using propensity score-matching, a new study is providing insight into the risk reduction and bleeding risk associated with various DOACs versus warfarin and one another in patients with nonvalvular atrial fibrillation and an increased gastrointestinal bleeding risk.
Read More
BMI Variability Can Predict Negative Outcomes in Chronic Kidney Disease
August 15th 2021An analysis of data from a national health database in South Korea suggests increased BMI variability was linked to a 66% greater risk of mortality and a 19% greater risk of heart attack and stroke in patients with chronic kidney disease.
Read More
Weight Fluctuations Could Predict Negative Outcomes in Chronic Kidney Disease
August 12th 2021An analysis of more than 50,000 patients with chronic kidney disease indicates increased BMI variability was tied to increased risk of mortality, need for kidney replacement therapy, and cardiovascular disease events.
Read More
COVID-19, Lockdowns Have Slowed Weight Loss Following Bariatric Surgery
August 12th 2021An analysis of patients from a hospital in Belgium provides insight into the impact of COVID-19 and lockdowns on weight loss and overall health on patients who underwent gastric bypass and were impacted by COVID-19 during their first postoperative year.
Read More
Data from a major registry suggests more than 90% of patients with heart failure with reduced ejection were discharged from the hospital without being prescribed sacubitril/valsartan (Entresto) and more than 90% of those patients never filled a prescription in the year following hospitalization.
Read More
A clinical pharmacist and nurse practitioner offer perspective on how the interchangeable biosimilar approval of Semglee impacts discussions around the cost of insulin for patients with diabetes and what they think is important for patients, providers, and pharmacists to know about the historic FDA approval.
Read More
Insulin for All? How Recent Developments Impact Insulin Affordability
August 4th 2021Titled, "Insulin for All? How Recent Developments Impact Insulin Affordability," this 3-part video series from Diana Isaacs, PharmD, and Lucia Novak, CRNP, explores how news from Walmart and Novo Nordisk and a historic approval from the US FDA impacts insulin affordability with the backdrop of the 100-year anniversary of the discovery of insulin.
Read More
For Stroke Survivors, Metabolic Syndrome Linked to Increased Risk of Second Events, Mortality
August 3rd 2021A meta-analysis with data from nearly 60k patients suggests presence of metabolic syndrome was associated with a 46% increase in risk of a second stroke and a 27% increase in risk of mortality among stroke survivors when compared to their counterparts without metabolic syndrome.
Read More
Eliminating Just 200 Calories Per Day Could Pay Major Dividends for Heart Health in Obesity
August 3rd 2021An ancillary study to the INFINITE trial details the benefits of caloric restriction plus exercise versus exercise alone on aortic stiffness measured using CMRI in older adults with obesity.
Read More
Using data from the National Health Interview Survey, investigators determined patients with diabetes in high deductible health plans were 28% more likely than those in traditional health plans to report cost-related medication non-adherence and this gap only widened when examining insulin users.
Read More
FDA Approves Semglee, Its First Interchangeable Biosimilar Insulin Product
July 29th 2021Announced on July 28, insulin glargine-yfgn (Semglee) becomes the first interchange biosimilar insulin product to receive approval in the FDA's history and is expected to be available by the end of the year.
Read More
Donor Hearts from Drug Users Safe for Transplant, Becoming More Common
July 28th 2021Despite the notion they are unsafe, a pair of studies demonstrate there were no significant differences in outcomes among heart transplant recipients receiving a donor heart based on a history of illicit drug use or overdose.
Read More
ACEs & ARBs Similar in Event Prevention, But ARBs Have Favorable Safety Profile
July 28th 2021A retrospective cohort study with data from nearly 4 million patients with hypertension from the US, Germany, and South Korea found ACEs and ARBs provide similar efficacy for prevention of cardiovascular events, but ACEs were associated with a greater risk of adverse events.
Read More
Excessive Caffeine Consumption Increases Renal Calcium Clearance, Australian Study Finds
July 27th 2021A study from the University of South Australia assessing the impact of high-dose, short-term caffeine consumption suggests increased consumption could increase renal calcium clearance by 77% in healthy patients.
Read More
Q&A on Heart Failure Prevention, with Javed Butler, MD
July 27th 2021Practical Cardiology sat down with Javed Butler, MD, following his presentation at ASPC 2021 to discuss how recent advances have impacted prevention of heart failure and how he views the role of primary care/internal medicine in primary prevention.
Read More
DAPA-CKD Analysis Suggests Farxiga is Safe, Effective in More Advanced Chronic Kidney Disease
July 24th 2021Data from a prespecified analysis of DAPA-CKD examining effects of dapagliflozin in patients with stage 4 CKD suggests the impact of the SGLT2 inhibitor in these patients was similar to those seen in the overall trial.
Read More
Exenatide Extended-Release Receives Historic FDA Approval for Use in Pediatric Type 2 Diabetes
July 23rd 2021With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.
Read More
Analysis of more than 40k Medicare beneficiaries suggests increased physical activity, whether it occurs as part of a rehabilitation or not, was associated with decreased risk of all-cause mortality and hospitalizations for heart failure in patients who recently received an implantable cardioverter-defibrillator.
Read More
Cognitive Decline in Older Women Could Signal Bone Loss, Increased Fracture Risk
July 22nd 2021Using data from more than 2000 patients followed for 16 years, a Garvan Institute of Medical Research-led team found cognitive decline in older women could help predict bone loss and fracture risk among these patients.
Read More
No Evidence Coffee Consumption Increases Risk of Arrhythmias, UCSF Study Finds
July 20th 2021Analysis of data from the UK Biobank cohort suggests consumption of coffee was not linked to an increased risk of arrhythmias, with some evidence indicating habitual use was linked to a decrease in incidence of atrial fibrillation or flutter and supraventricular tachycardia.
Read More
Dapagliflozin Safe and Effective in Stage 4 Chronic Kidney Disease, DAPA-CKD Analysis Finds
July 20th 2021A prespecified analysis of patients with stage 4 CKD from DAPA-CKD suggests the magnitude of effects seen with dapagliflozin use among these patients was similar to that seen among patients with normal to moderately impaired kidney function from the trial.
Read More